Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention

Hepatology Research

Volumn 46, Issue 7, 2016, Pages 686-696

  Witzigmann, Dominik ^a   Quagliata, Luca ^b   Schenk, Susanne H ^a   Quintavalle, Cristina ^b   Terracciano, Luigi M ^b   Huwyler, Jörg ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

asialoglycoprotein receptor; drug delivery; hepatocyte; liver disease; nanomedicine

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR 1; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; T LYMPHOCYTE; TISSUE MICROARRAY; UPREGULATION;

EID: 84975048579     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12599     Document Type: Article

References (70)

1. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521–6.
2. Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012; 161: 188–97.
3. Reddy LH, Couvreur P. Nanotechnology for therapy and imaging of liver diseases. J Hepatol 2011; 55: 1461–6.
4. Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007; 104: 12982–7.
5. Sebestyén MG, Wong SC, Trubetskoy V, et al. Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes. Methods Mol Biol 2015; 1218: 163–86.
6. Kanasty R, Dorkin JR, Vegas A, et al. Delivery materials for siRNA therapeutics. Nat Mater 2013; 12: 967–77.
7. Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J Control Release 2015; 200: 138–57.
8. Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 2002; 7: d717–25.
9. Steirer LM, Park EI, Townsend RR, et al. The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose. J Biol Chem 2009; 284: 3777–83.
10. Park EI, Mi Y, Unverzagt C, et al. The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc. Proc Natl Acad Sci U S A 2005; 102: 17125–9.
11. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995; 75: 591–609.
12. Ashwell G, Harford J. Carbohydrate-Specific Receptors of the Liver. Annu Rev Biochem 1982; 51: 531–54.
13. Rensen PC, Sliedregt LA, Ferns M, et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem 2001; 276: 37577–84.
14. Zhou X, Zhang M, Yung B, et al. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine 2012; 7: 5465–74.
15. Xiao Y, Zhang H, Zhang Z, et al. Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo. Int J Nanomedicine 2013; 8: 3033–50.
16. Wang X, Sun H, Meng F, et al. Galactose-decorated reduction-sensitive degradable chimaeric polymersomes as a multifunctional nanocarrier to efficiently chaperone apoptotic proteins into hepatoma cells. Biomacromolecules 2013; 14: 2873–82.
17. Barrett SE, Burke RS, Abrams MT, et al. Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates. J Control Release 2014; 183: 124–37.
18. Nair JK, Willoughby JLS, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014; 136: 16958–61.
19. Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 2014; 42: 8796–807.
20. Castaño A, Drachman BM, Judge D, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 2014; 20: 163–78.
21. Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection. Mol Ther 2013; 21: 973–85.
22. Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. J Hepatol 2013; 59: 1354–9.
23. Lorenzer C, Dirin M, Winkler A-M, et al. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203C: 1–15.
24. Yan J-J, Liao J-Z, Lin J-S, et al. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems. Tumour Biol 2014; 36: 55–67.
25. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448–58.
26. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223–40.
27. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259–62.
28. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
29. Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002; 10: 73–9.
30. Peng D-J, Sun J, Wang Y-Z, et al. Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther 2007; 14: 66–73.
31. Zhang M, Zhou X, Wang B, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release 2013; 168: 251–61.
32. Stoller JK, Aboussouan LS. alpha 1-antitrypsin deficiency. Lancet 2005; 365: 2225–36.
33. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–8.
34. Gaumet M, Vargas A, Gurny R, et al. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008; 69: 1–9.
35. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271–84.
36. van Furth R, Cohn ZA, Hirsch JG, et al. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ 1972; 46: 845–52.
37. Bider MD, Cescato R, Jenö P, et al. High-affinity ligand binding to subunit H1 of the asialoglycoprotein receptor in the absence of subunit H2. Eur J Biochem 1995; 230: 207–12.
38. Fuhrer C, Geffen I, Huggel K, et al. The two subunits of the asialoglycoprotein receptor contain different sorting information. J Biol Chem 1994; 269: 3277–82.
39. Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008; 129: 899–906.
40. Quagliata L, Matter MS, Piscuoglio S, et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 2014; 59: 911–23.
41. Lundquist P, Englund G, Skogastierna C, et al. Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition. Drug Metab Dispos 2014; 42: 448–58.
42. Weigel PH, Oka JA. The surface content of asialoglycoprotein receptors on isolated hepatocytes is reversibly modulated by changes in temperature. J Biol Chem 1983; 258: 5089–94.
43. Kato J, Mogi Y, Kohgo Y, et al. Suppressive effect of ethanol on the expression of hepatic asialoglycoprotein receptors augmented by interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha. J Gastroenterol 1998; 33: 855–9.
44. Schwartz AL, Geuze HJ, Lodish HF. Recycling of the asialoglycoprotein receptor: biochemical and immunocytochemical evidence. Philos Trans R Soc Lond B Biol Sci 1982; 300: 229–35.
45. Eto T, Takahashi H. Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat Med 1999; 5: 577–81.
46. van Zijl F, Mikulits W. Hepatospheres: Three dimensional cell cultures resemble physiological conditions of the liver. World J Hepatol 2010; 2: 1–7.
47. Li Y, Tang Z-Y, Hou J-X. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol 2012; 9: 32–43.
48. Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009; 90: 367–86.
49. Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013; 7: 206–23.
50. Bagi CM, Andresen CJ. Models of hepatocellular carcinoma and biomarker strategy. Cancers (Basel) 2010; 2: 1441–52.
51. Detampel P, Witzigmann D, Krähenbühl S, et al. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes. J Drug Target 2013; 22: 232–41.
52. Kim TH, Park IK, Nah JW, et al. Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials 2004; 25: 3783–92.
53. Ma J, Huang C, Yao X, et al. Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs. PLoS One 2012; 7: e46096.
54. Trahtenherts A, Benhar I. An Internalizing Antibody Specific for the Human Asialoglycoprotein Receptor. Hybridoma 2009; 28: 225–33.
55. Khorev O, Stokmaier D, Schwardt O, et al. Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem 2008; 16: 5216–31.
56. Li J, Chen L, Zhang X, et al. Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. PLoS One 2014; 9: e96185.
57. Yuzugullu H, Benhaj K, Ozturk N, et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009; 8: 90.
58. Shia MA, Lodish HF. The two subunits of the human asialoglycoprotein receptor have different fates when expressed alone in fibroblasts. Proc Natl Acad Sci U S A 1989; 86: 1158–62.
59. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 1990; 29: 10009–18.
60. Hyodo I, Mizuno M, Yamada G, et al. Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. Liver 1993; 13: 80–5.
61. Trerè D, Fiume L, De Giorgi LB, et al. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 1999; 81: 404–8.
62. Shi B, Abrams M, Sepp-Lorenzino L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem 2013; 61: 901–9.
63. Rigopoulou EI, Roggenbuck D, Smyk DS, et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev 2012; 12: 260–9.
64. Ojha T, Rizzo L, Storm G, et al. Image-guided drug delivery: preclinical applications and clinical translation. Expert Opin Drug Deliv 2015; 12: 1203–7.
65. Kokudo N, Vera DR, Makuuchi M. Clinical application of TcGSA. Nucl Med Biol 2003; 30: 845–9.
66. Kobayashi K, Hattori N, Manabe O, et al. Postoperative Assessment of Hepatic Asialoglycoprotein Receptor Function with Tc-99 m GSA: The Safety Margin of Resection Size in Living Donor Liver Transplantation. Ann Transplant 2015; 20: 51–8.
67. Huang G, Diakur J, Xu Z, et al. Asialoglycoprotein receptor-targeted superparamagnetic iron oxide nanoparticles. Int J Pharm 2008; 360: 197–203.
68. Seymour LW, Ferry DR, Anderson D, et al. Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin. J Clin Oncol 2002; 20: 1668–76.
69. Julyan PJ, Seymour LW, Ferry DR, et al. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release 1999; 57: 281–90.
70. Theek B, Rizzo LY, Ehling J, et al. The Theranostic Path to Personalized Nanomedicine. Clin Transl Imaging 2014; 2: 66–76.